Sánchez, RicardoAyala, RosaMartinez-Lopez, Joaquin2019-07-012019-07-012019-06-10Int J Mol Sci. 2019;20(11). pii: E2832.1422-0067http://hdl.handle.net/20.500.12105/7827Ultra-deep next-generation sequencing has emerged in recent years as an important diagnostic tool for the detection and follow-up of tumor burden in most of the known hematopoietic malignancies. Meticulous and high-throughput methods for the lowest possible quantified disease are needed to address the deficiencies of more classical techniques. Precision-based approaches will allow us to correctly stratify each patient based on the minimal residual disease (MRD) after a treatment cycle. In this review, we consider the most prominent ways to approach next-generation sequencing methodologies to follow-up MRD in hematological neoplasms.engVoRhttp://creativecommons.org/licenses/by-nc-sa/4.0/clonal evolutionhematological neoplasmshigh-throughput sequencingminimal residual diseasenext-generation sequencingAtribución-NoComercial-CompartirIgual 4.0 Internacional311856712011283210.3390/ijms201128321422-0067International journal of molecular sciencesopen access